AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
- Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023
- ACI-24.060 anti-amyloid-beta vaccine for Alzheimer’s disease (AD) showed positive initial safety and immunogenicity in Phase 1b/2 ABATE trial; further interim data expected in H2 2023; first amyloid plaque PET imaging results anticipated in 2024
- ACI-35.030 anti-pTau vaccine for AD selected for further development by partner; anticipated H2 2023 initiation of next trial in AD to be followed by milestone payment
- 2022 cash burn of CHF 70.9 million was better than guidance (2022: CHF 75-80 million) resulting in strong end of year financial position of CHF 122.6 million providing runway into Q3 2024, excluding potential milestone payments
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the year ended December 31, 2022, and provided a corporate update.